|
|
Home > Healthcare > Pharmaceutical > Drug Discovery
New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
|
| Published Date:
May 2009
Published By:
Datamonitor
Page Count:
264
Order Code:
R313-51599
|
|
|
|
With industry consolidation, the economic downturn, and an increasing threat from generics, pharma companies are coming under greater pressure to fill their pipelines with innovative drugs. However, despite the costs and risks involved in drug development, the pharma industry is finding new ways to streamline the R&D process in an effort to increase efficiency and output.
Scope- Overview of ongoing trends affecting R&D and how these will shape Pharma in the future
- R&D Insight from Big Pharma industry executives
- Analysis into Pharma's evolving R&D portfolio between 2006 and 2009, in addition to examination of pipeline M&A and collaborative deals
- Case studies of innovative strategies used to maximize R&D productivity
Highlights- GlaxoSmithKline, Pfizer and AstraZeneca have the largest preclinical and clinical drug pipelines, each with approximately 200 candidates in development as of March 2009. In terms of volume growth Genentech's pipeline grew the most in terms of percentage points, almost doubling (up 95%).
- Over the period 200609, the average growth per therapy area was 9.4%. In terms of percentage points, the therapy area experiencing the largest growth in pipeline candidates was ophthalmology, while cardiovascular pipelines saw the largest decline, indicative of Pharma's shift towards niche markets and personalized medicines.
- The number of pipeline deals made during 200608 have steadily declined. However, with Biotech finding it hard to fund R&D at present, and with many companies going bankrupt, this will affect Big Pharma in the longer term, which is increasingly downsizing internal research becoming ever reliant on external sources.
Reasons to Purchase- Identify R&D trends in today's pharmaceutical market, and how these affect productivity and return on investment
- Understand how a diverse range of strategies can improve R&D productivity and output, and identify how these can best be implemented
- Gain insight into how to optimize R&D processes and increase the chance of clinical, and ultimately commercial success
|
Similar Products
• Antidiabetics in Australia Market Forecast
Published Oct 2009 by Datamonitor
• Plunkett's Health Care Technologies Overview 2010 (Summary)
Published Oct 2009 by Plunkett Research, Ltd.
• Pipeline Insight: Disease Modification in Rheumatoid Arthritis - New drug targets compete in crowded market
Published Oct 2009 by Datamonitor
• Commercial Insight: Parkinson's Disease - Japan and Europe to drive total market growth
Published Oct 2009 by Datamonitor
• Commercial Insight: Antidepressants - Novel mechanism offers hope in depressed market
Published Oct 2009 by Datamonitor
• Parkinson's Disease Market Forecast
Published Oct 2009 by Datamonitor
• Orphan Drug Strategies
Published Oct 2009 by Datamonitor
• Pipeline Insight: HIV - The Age of Convenience
Published Oct 2009 by Datamonitor
• The World Market for Addiction Disorders, 2009 - 2016
Published Oct 2009 by Spectra Intelligence
|
|
|
|
0 items
